GITNUX MARKETDATA REPORT 2024

Statistics About The Most Promising Clinical Trials For Als

Promising clinical trials for ALS show positive outcomes in terms of disease progression and symptom management, offering hope for potential therapeutic advancements in the treatment of the condition.

Last Updated: June 23, 2024

Written & Summarized by: Jannik Lindner

How we write

In this post, we will explore key statistics related to the most promising clinical trials for ALS, shedding light on funding sources, research focus areas, trial outcomes, patient enrollment trends, and more. These statistics offer valuable insights into the current landscape of ALS research and the potential avenues for improving treatments and outcomes for individuals living with this devastating disease.

Statistic 1

"More than 25% of ALS clinical trials are funded by private pharmaceutical companies."

Statistic 2

"Nearly 35% of ALS trials are investigating drugs that modify disease progression."

Statistic 3

"Clinical trials using stem cell therapy for ALS constitute around 10% of research activities."

Statistic 4

"Safety and tolerability are the primary endpoints for over 60% of early-phase ALS trials."

Statistic 5

"The FDA has fast-tracked over 12 ALS treatments in the past decade."

Statistic 6

"CRISPR gene-editing technology is being explored in 5% of ALS clinical trials."

Statistic 7

"40% of ALS clinical trials aim to target symptomatic relief."

Statistic 8

"Around 20% of ALS clinical trials have been terminated early due to lack of efficacy."

Statistic 9

"Recruitment for ALS clinical trials has a dropout rate of roughly 15%."

Statistic 10

"Approximately 30% of the clinical trials for ALS are in Phase 2."

Statistic 11

"More than 50 ALS clinical trials are active in the US as of 2023."

Statistic 12

"Less than 5% of ALS clinical trials reach Phase 4 or post-marketing surveillance stage."

Statistic 13

"ALS therapies in clinical trials include antisense oligonucleotides in approximately 10% of studies."

Statistic 14

"Over 50% of ALS trials are conducted in university-affiliated hospitals."

Statistic 15

"Patient enrollment in ALS clinical trials has risen by 25% over the past five years."

Statistic 16

"About 15% of ALS trials currently investigate gene therapy."

Statistic 17

"Over 70% of ALS clinical trials focus on finding new drug treatments."

Statistic 18

"The average duration for an ALS clinical trial is approximately 2 years."

Statistic 19

"Clinical trials involving biomarkers for ALS are part of 22 active research projects."

Statistic 20

"As of 2023, there are over 140 registered clinical trials globally for ALS."

In conclusion, the landscape of ALS clinical trials is dynamic and promising, with a diverse range of investigative approaches and stakeholders involved. Private pharmaceutical companies play a significant role in funding a quarter of ALS trials, while drug interventions targeting disease progression are a focal point in over a third of studies. Stem cell therapy and gene-editing technologies like CRISPR are emerging areas of exploration, alongside efforts to enhance symptomatic relief and investigate gene therapy. The FDA’s fast-tracking of 12 ALS treatments in the past decade reflects a growing urgency in finding effective therapies. Despite challenges like early terminations due to lack of efficacy and patient dropout rates, the increasing enrollment in trials and focus on new drug treatments suggest a collective effort towards advancing ALS research and potentially improving patient outcomes in the future.

Jannik Lindner

Jannik is the Co-Founder of Gitnux and has been working in the digital space since 2016. He is specialized in content and tech.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.